Coherence Neuro snags $45M to pair AI with brain implants for aggressive cancer

A new player at the intersection of medical AI and neurotech is drawing heavy interest from top investors. US‑based Coherence Neuro has raised a $45 million Series A round to develop an implantable device for treating malignant brain tumors, particularly hard‑to‑treat glioblastoma. Backers include Founders Fund and the OpenAI Startup Fund, signaling strong conviction that AI‑enabled hardware can unlock new frontiers in cancer care.

Coherence Neuro’s approach combines a tiny brain implant with a cloud‑based AI platform. The system is designed to continuously monitor tumor dynamics and neural activity, then adjust stimulation patterns and other treatment parameters in near real time. By learning from rich streams of physiological data, the AI aims to personalize therapy for each patient far beyond what today’s protocols allow.

The concept also raises complex regulatory and ethical questions. Invasive devices that rely on adaptive algorithms face rigorous US Food and Drug Administration review, alongside heightened scrutiny over data protection and algorithmic transparency. The size of this funding round highlights both investor enthusiasm for “AI + hardware” in medicine and the substantial resources required to navigate safety trials and compliance.